Immuno oncology News and Research

RSS

Nanobiotix receives FDA approval for first immuno-oncology trial

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

26 Dec 2017

Novel compound along with checkpoint inhibitors may enhance immune response in melanoma patients

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

New intelligence tool provides clarity to scientists in booming immuno-oncology field

Hanson Wade, the London-based life sciences knowledge services specialist, has launched IO Combination Trials Intelligence (www.beacon-intelligence.com), to provide clarity to scientists and strategists in the booming immuno-oncology combination field of study.

23 Nov 2017

Philips launches proof-of-concept pilot for digital pathology services at ehi Live 2017

Royal Philips, a leader in health technology, today announced the launch of a proof-of-concept pilot for digital pathology services at a large, multi-region, scale. Announced at ehi Live, the pilot will last up to 12 months and is designed to establish ease-of-adoption for a fully integrated and digitised national pathology service, across Scottish NHS providers.

From Philips Healthcare 2 Nov 2017

Vedantra and Neon Therapeutics extend research alliance to develop impactful cancer therapies

Vedantra Pharmaceuticals, Inc., an immunotherapy company focused on developing products to treat cancer and infectious disease, and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T-cell therapies to treat cancer, announced today that the companies have extended their non-exclusive research alliance.

31 Oct 2017

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

28 Oct 2017

Salk scientists receive $2.5 million funding to conduct pancreatic cancer clinical study

Salk Professor and HHMI Investigator Ronald Evans has been awarded $2.5 million by Stand Up 2 Cancer (SU2C) as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer.

12 Oct 2017

Scientists reveal new method to reprogram specific T cells

When the immune system is imbalanced, either due to overly-active cells or cells that suppress its function, it causes a wide range of diseases, from psoriasis to cancer.

2 Aug 2017

Shaping the future of oncology treatment

Victories Over Cancer is about enabling those affected by cancer to enjoy more of life’s meaning full moments and making cancer more manageable. At Janssen, we're really thinking about the elimination of cancer, and we take a very deliberate approach to that.

2 Aug 2017

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

5 Jun 2017

Addressing unmet needs in prostate cancer

Prostate cancer is the second most diagnosed cancer globally with over a million men diagnosed worldwide. We are fortunate in that better diagnostic techniques and better awareness means that men are often being diagnosed earlier, which gives them a better chance of being cured.

19 Apr 2017

MSU and Venn Therapeutics develop promising therapy to delay B16 melanoma tumor growth

Michigan State University researchers presented promising cancer therapy results at the American Association for Cancer Research International Meeting in Washington, DC.

5 Apr 2017

Essen BioScience Launches the IncuCyte® S3 Live-Cell Analysis Platform

Essen BioScience, a pioneer and leader in the field of cell-based assays and instrumentation used for drug discovery and basic research, has launched the IncuCyte® S3 live-cell analysis platform for real-time, automated measurements of cell health, proliferation, movement and function directly inside a standard incubator.

From Sartorius 3 Apr 2017

Evolution of immuno-oncology

Immuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).

13 Mar 2017

Immuno oncology News and Research

Nanobiotix receives FDA approval for first immuno-oncology trial

Novel compound along with checkpoint inhibitors may enhance immune response in melanoma patients

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

New first line combination therapy shows promising results in patients with advanced NSCLC

New intelligence tool provides clarity to scientists in booming immuno-oncology field

Philips launches proof-of-concept pilot for digital pathology services at ehi Live 2017

Vedantra and Neon Therapeutics extend research alliance to develop impactful cancer therapies

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

Salk scientists receive $2.5 million funding to conduct pancreatic cancer clinical study

Scientists reveal new method to reprogram specific T cells

Shaping the future of oncology treatment

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Addressing unmet needs in prostate cancer

MSU and Venn Therapeutics develop promising therapy to delay B16 melanoma tumor growth

Essen BioScience Launches the IncuCyte® S3 Live-Cell Analysis Platform

Evolution of immuno-oncology

Sartorius to Acquire Real-Time Live-Cell Analysis Pioneer and Leader Essen BioScience

Essen Bioscience to Showcase IncuCyte® Live-cell Analysis System and Applications at AACR, Booth #1365

ICLIO white paper spotlights top-level concerns in delivering immunotherapies for cancer

Essen BioScience’s IncuCyte live-cell analysis platform cited in more than 1000 publications

A best-practice guide for laboratory services in oncology trials eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News